Company Overview

A growing base of clinical research shows the rapid induction of mild hypothermia (32°C - 33°C) during periods of ischemia can protect tissue from ischemic damage. Furthermore, recent studies have shown that the earlier cooling is achieved in the setting of ischemia and reperfusion, the better the outcome.^1,2,3

To address this need, INNERCOOL developed the Celsius Control System™ a proprietary endovascular technology to rapidly induce, precisely maintain and gradually or rapidly reverse mild hypothermia.

INNERCOOL has received FDA clearance for the Celsius Control System to induce, maintain and reverse mild hypothermia in neurosurgical patients in surgery and recovery/intensive care. Subsequent indications for the CCS have also been obtained in fever control and cardiac surgery. The company has received the CE mark allowing the Celsius Control System to be marketed in the European Community.

INNERCOOL prides itself on conducting and publishing well designed clinical studies to show not only the performance, but the safety of the Celsius Control System. INNERCOOL is the only hypothermia company to perform and publish a large (n=153) multi-center, prospective, randomized, controlled study (TCAS) showing how rapidly the CCS cools patients to 33°C as well as maintain 33°C as a target temperature over time and rewarm patients back to normothermia. Additional INNERCOOL studies and manuscripts can be viewed by visiting our Clinical Abstracts and Presentations page.

The Company has aggressively developed a broad intellectual property portfolio in the emerging field of temperature control therapy. The company has nearly 100 issued U.S. patents and numerous patents and patent applications on file in the U.S. and around the world. INNERCOOL was founded in 1998 and is headquartered in San Diego, California, USA.

INNERCOOL is compliant with ISO 9001, EN 46001 and ISO 13485 quality standards.

¹Abella, B et al. ãIntra-Arrest Cooling Improves Outcomes in a Murine Cardiac Arrest Modelä, Circulation. June 8, 2004. pg 2790

²Nozari, A. et al "Critical time window for intra-arrest cooling with cold saline flush in a dog model of cardiopulmonary resuscitation" Circulation. 2006 Jun 13; 113(23):2690-6.

³Tanimoto, H et al ãRapidly Induced Hypothermia with extracorporeal lung and heart assist improves the neurological outcome after prolonged cardiac arrest in dogsä Resuscitation 2006 Nov 9. PMID: 17097794